Quotient Therapeutics

Quotient Therapeutics is the first company to systematically study the genetic variations and evolution of trillions of cells in the human body. The company's somatic genomics platform unveils new connections between genes and diseases across a wide range of therapeutic areas, enabling the discovery of transformative drugs aimed at curing, preventing, or reversing diseases. Quotient was founded in 2022 by Flagship Pioneering and is supported by experts in the field of somatic genetics.